C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) A61K 39/395 (2006.01) A61P 31/04 (2006.01) C07K 16/12 (2006.01)
Patent
CA 2754900
Disclosed are a humanized monoclonal antibody against PcrV or a part thereof and a pharmaceutical composition comprising the humanized monoclonal antibody or a part thereof as an active ingredient, both of which are effective means for the treatment of infectious diseases, particularly infectious diseases induced by Pseudomonas aeruginosa. Specifically, the humanized monoclonal antibody has an excellent inhibitory activity on the cytotoxicity of Pseudomonas aeruginosa against a target cell. The humanized monoclonal antibody has a high affinity for PcrV.
La présente invention concerne un anticorps monoclonal humanisé contre PcrV ou une partie de celui-ci et une composition pharmaceutique comprenant l'anticorps monoclonal humanisé ou une partie de celui-ci en tant que substance active, tous deux étant des moyens efficaces pour le traitement de maladies infectieuses, en particulier des maladies infectieuses induites par Pseudomonas aeruginosa. Spécifiquement, l'anticorps monoclonal humanisé a une excellente activité inhibitrice sur la cytotoxicité de Pseudomonas aeruginosa contre une cellule cible. L'anticorps monoclonal humanisé a une affinité élevée pour PcrV.
Kawamoto Keiko
Numata Yoshito
Sato Takafumi
Tsuji Toshinaga
Yamano Yoshinori
Mccarthy Tetrault Llp
Shionogi & Co. Ltd.
LandOfFree
Humanized pcrv antibody having anti-pseudomonal activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized pcrv antibody having anti-pseudomonal activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized pcrv antibody having anti-pseudomonal activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1388118